{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:31:17Z","timestamp":1791279077951,"version":"4.1.0"},"reference-count":42,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,1,12]],"date-time":"2012-01-12T00:00:00Z","timestamp":1326326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pigment Cell Melanoma Res"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>BRAF inhibition is highly active in <jats:italic>BRAF\u2010<\/jats:italic>mutant melanoma, but the degree and duration of responses is quite variable. Improved understanding of the mechanisms of de novo resistance may lead to rational therapeutic strategies with improved efficacy. Proteomic analysis of <jats:italic>BRAF\u2010<\/jats:italic>mutant, PTEN\u2010wild\u2010type human melanoma cell lines treated with PLX4720 demonstrated that sensitive and de novo resistant lines exhibit similar RAS\u2010RAF\u2010MEK\u2010ERK pathway inhibition, but the resistant cells exhibited durable activation of S6 and P70S6K. Treatment with the mTOR inhibitor rapamycin blocked activation of P70S6K and S6, but it also increased activation of AKT and failed to induce cell death. Combined treatment with rapamycin and PX\u2010866, a PI3K inhibitor, blocked the activation of S6 and AKT and resulted in marked cell death when combined with PLX4720. The results support the rationale for combined targeting of BRAF and the PI3K\u2010AKT pathways and illustrate how target selection will be critical to such strategies.<\/jats:p>","DOI":"10.1111\/j.1755-148x.2011.00950.x","type":"journal-article","created":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T04:55:29Z","timestamp":1324011329000},"page":"248-258","source":"Crossref","is-referenced-by-count":96,"title":["Role and therapeutic potential of PI3K\u2010mTOR signaling in de novo resistance to BRAF inhibition"],"prefix":"10.1111","volume":"25","author":[{"given":"W.","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. N.","family":"Vashisht Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. E.","family":"Woodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,12]]},"reference":[{"issue":"1","key":"e_1_2_8_2_1","first-page":"S11","article-title":"High\u2010dose recombinant interleukin\u20102 therapy in patients with metastatic melanoma: long\u2010term survival update","volume":"6","author":"Atkins M.B.","year":"2000","journal-title":"Cancer J. Sci. Am."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.4799"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09454"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3641"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4751"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1985"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603291"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002011"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700026"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0902"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2010.00685.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08833"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.12.040"},{"key":"e_1_2_8_16_1","first-page":"5198","article-title":"Suppression of BRAF(V599E) in human melanoma abrogates transformation","volume":"63","author":"Hingorani S.R.","year":"2003","journal-title":"Cancer Res."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20481"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2010.48"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2225"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09627"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207785"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M402591200"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.8503"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nop058"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.44"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.02.031"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6787"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09626"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09626"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2925"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2336"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2954"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10662"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0140"},{"key":"e_1_2_8_35_1","unstructured":"Sosman J. Kim K. Schuchter L.et\u00a0al.(2010)Phase II study of continuous oral dosing of RG7204 (PLX4032) in previously treated patients with BRAFV600E mutation\u2010positive metastatic melanoma. In Society of Melanoma Research 2010; 7th International Melanoma Congress & 4th Meeting of Interdisciplinary Melanoma\/Skin Cancer Centers (Sydney Australia)."},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207812"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711741105"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041245"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.11.023"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.2312"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(04)00215-6"},{"key":"e_1_2_8_42_1","article-title":"Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF","author":"Xing F.","year":"2011","journal-title":"Oncogene"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0646"}],"container-title":["Pigment Cell &amp; Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-148X.2011.00950.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1755-148X.2011.00950.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T05:59:40Z","timestamp":1698645580000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-148X.2011.00950.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,12]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1111\/j.1755-148X.2011.00950.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1755-148x.2011.00950.x","archive":["Portico"],"relation":{},"ISSN":["1755-1471","1755-148X"],"issn-type":[{"value":"1755-1471","type":"print"},{"value":"1755-148X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,12]]}}}